PT - JOURNAL ARTICLE AU - Dowey, Rebecca AU - Cole, Joby AU - Thompson, A A Roger AU - Huang, Chenghao AU - Whatmore, Jacob AU - Iqbal, Ahmed AU - Bradley, Kirsty L AU - McKenzie, Joanne AU - Hull, Rebecca C AU - Lawrie, Allan AU - Condliffe, Alison M AU - Kiss-Toth, Endre AU - Sabroe, Ian AU - Prince, Lynne R TI - Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the PKC inhibitor ruboxistaurin AID - 10.1101/2021.08.24.21262336 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.24.21262336 4099 - http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262336.short 4100 - http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262336.full AB - Neutrophil extracellular traps (NETs) are web-like DNA and protein lattices which are expelled by neutrophils to trap and kill pathogens, but which cause significant damage to the host tissue. NETs have emerged as critical mediators of lung damage, inflammation and thrombosis in COVID-19 and other diseases, but there are no therapeutics to prevent or reduce NETs that are available to patients. Here, we show that neutrophils isolated from hospitalised patients with COVID-19 produce significantly more NETs in response to LPS compared to cells from healthy control subjects. A subset of patients were captured at follow-up clinics (3-4 month post-infection) and while LPS-induced NET formation is significantly lower at this time point, it remains elevated compared to healthy controls. LPS- and PMA-induced NETs were significantly inhibited by the protein kinase C (PKC) inhibitor ruboxistaurin. Ruboxistaurin-mediated inhibition of NETs in healthy neutrophils reduces NET-induced epithelial cell death. Our findings suggest ruboxistaurin could reduce proinflammatory and tissue-damaging consequences of neutrophils during disease, and since it has completed phase III trials for other indications without safety concerns, it is a promising and novel therapeutic strategy for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by University of Sheffield PhD Studentships to RD and JM, The Rosetrees Trust (X/154753-12) (KLB), the Medical Research Foundation (MRF-145-0004-TPG-AVISO) (RCH), the UK Coronavirus Immunology Consortium (UK-CIC) and Medical Research Council AMR cross-council funding to the SHIELD consortium Optimising Innate Host Defence to Combat Antimicrobial Resistance (MRNO2995X/1). AART is supported by a BHF Intermediate Clinical Fellowship (FS/18/13/33281).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hospitalised patients with COVID-19 (n=39) admitted to the Royal Hallamshire Hospital, Sheffield, UK were recruited to the study and provided fully informed consent via The Sheffield Teaching Hospitals Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS), REC 18/YH/0441, IRAS 248890, project title: Establishing the magnitude, breadth and durability of SARS-CoV-2 induced activation of innate immune blood cells (COVID-19 INNATE)). Ethical approval was given by the Yorkshire & The Humber - Sheffield Research Ethics Committee. Blood from healthy volunteers was taken according to the protocol: The control of innate immunity, host-pathogen interactions and leukocyte function in healthy volunteers (REC 05/Q2305/4, STH13927). Ethical approval was given by the Yorkshire & The Humber - Sheffield Research Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.